Literature DB >> 31204484

Vacation frequency is associated with metabolic syndrome and symptoms.

Bryce Hruska1, Sarah D Pressman2, Kestutis Bendinskas3, Brooks B Gump1.   

Abstract

Objective: To examine the extent to which vacationing behavior is associated with metabolic outcomes. Specifically, we consider how total vacation episodes and total vacation days from the past 12 months relate to metabolic syndrome and metabolic symptoms.Design: Sixty-three workers eligible for paid vacation attended a lab visit during which their blood was drawn and they completed an interview assessing vacationing behavior in the past 12 months.Main outcome measures: Metabolic syndrome and metabolic symptoms are the main outcome measures.
Results: Over the past 12 months, participants took approximately five vacations (M = 5.44, SD = 3.16) and used about 2 weeks of their paid vacation days (M = 13.80, SD = 7.25). Participants rated vacations positively, expressing low levels of travel-, childcare- and financial burden-related stress. As vacation episodes increased, metabolic syndrome incidence (OR = 0.76, p = 0.051) and number of metabolic symptoms met (IRR = 0.92, p = 0.035) decreased. Notably, risk for metabolic syndrome decreased by nearly a quarter with each additional vacation taken by participants.Conclusions: Overall, vacations are experienced as positive events. This positive subjective experience may translate into physical health benefits given that vacation frequency may protect against metabolic syndrome and symptoms.

Entities:  

Keywords:  Vacation; metabolic symptoms; metabolic syndrome; paid time off; physical health; recovery experience

Mesh:

Year:  2019        PMID: 31204484     DOI: 10.1080/08870446.2019.1628962

Source DB:  PubMed          Journal:  Psychol Health        ISSN: 0887-0446


  1 in total

1.  Seroprevalence of hepatitis E virus antibodies in adults and children from upstate New York: A cross-sectional study.

Authors:  Brittany L Kmush; Amelia M Lu; Taylor Spillane; Bryce Hruska; Brooks B Gump; Kestutis G Bendinskas
Journal:  PLoS One       Date:  2021-01-26       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.